

Ruxolitinib for treatment of refractory hemophagocytic lymphohistiocytosis

Larisa Broglie,^{1,2,*} Lauren Pommert,^{2,3,*} Sridhar Rao,⁴ Monica Thakar,^{1,2} Rachel Phelan,^{1,2} David Margolis,^{1,2} and Julie Talano^{1,2}

¹Division of Hematology, Oncology, and Blood and Marrow Transplant, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI; ²Children's Hospital of Wisconsin, Milwaukee, WI; ³Division of Hematology, Oncology, and Blood and Marrow Transplant, Department of Pediatrics, Children's Hospital of Wisconsin, Milwaukee, WI; and ⁴Blood Research Institute, Medical College of Wisconsin, Milwaukee, WI

Key Points

- Optimal salvage therapy for refractory HLH is unknown.
- In our patient, ruxolitinib treatment led to clinical remission of refractory HLH.

Introduction

Hemophagocytic lymphohistiocytosis (HLH) is a potentially fatal illness characterized by impaired natural killer and cytotoxic T-cell function. Patients present with systemic inflammation and multisystem organ dysfunction; if untreated, HLH results in death. The clinical picture can evolve, and thus, there should be a high degree of clinical suspicion for this diagnosis in critically ill patients and a low threshold for sending testing (diagnostic criteria noted in Figure 1) to ensure timely diagnosis and initiation of treatment.¹

Eighty percent of patients have at least a partial response to front-line therapy with dexamethasone and etoposide.² However, for the 20% who are refractory to therapy, there is no consensus on optimal second-line treatment. Alemtuzumab, infliximab, anakinra, and others have been suggested as possible salvage treatment options with variable success.^{2,3} Recently, ruxolitinib, a Janus kinase (JAK) 1/2 inhibitor, has shown promise in mouse models of primary and secondary HLH. When administered empirically to perforin-deficient mice, ruxolitinib inhibits interferon γ (IFN- γ), interleukin-6 (IL-6), and IL-12 production and prevents clinical symptoms of HLH from developing.⁴ Similarly, when ruxolitinib is administered after HLH symptom onset, cytokine production and tissue damage are decreased, leading to improved survival in mice.⁵ The dramatic effect of ruxolitinib in murine models has led to interest in its use clinically for refractory HLH.

Here we present a case of a patient with refractory HLH who was clinically deteriorating and experienced a dramatic improvement with ruxolitinib therapy.

Case description and methods

An 11-year-old previously healthy boy, recently emigrated from Burma, was admitted with complaints of extremity myalgias and difficulty walking. After admission, he developed daily high-spiking fevers of 39°C to 40°C and a pleural effusion requiring chest-tube placement. Despite initial clinical improvement, he had persistent fevers and developed liver dysfunction, respiratory failure, and acute renal insufficiency. An extensive infectious workup was negative, and his symptoms and laboratory values did not improve with broad-spectrum antimicrobials. Rheumatologic, immunodeficient, and oncologic causes were investigated and found to be negative (Table 1). Because of his persistent fevers, multisystem organ dysfunction, and continued rise in ferritin (>20 000 ng/mL), there was concern about evolving HLH (Figure 1). Although initial bone marrow evaluation did not show evidence of hemophagocytosis, he met clinical criteria for HLH, and with acute clinical decline requiring intubation and ionotropic support, HLH-directed therapy was initiated with dexamethasone (10 mg/m² per day) and etoposide (112.5 mg/m²; dose adjusted for renal insufficiency).

Initially, he had evidence of clinical response, and 3 days after the start of etoposide, he was extubated and weaned off of ionotropic support and had modest improvement in his coagulopathy and renal function. However, he continued to have daily fevers, splenomegaly, and laboratory criteria for HLH.

He then experienced acute clinical deterioration after 10 days of HLH treatment, despite receiving a dose of anakinra (1 mg/kg IV); he developed severe pulmonary edema leading to respiratory failure,




Figure 1. Patient's laboratory and clinical response to treatment. (A) Our patient's clinical and laboratory abnormalities and how he met criteria for diagnosis of HLH noted at initial diagnosis, at diagnosis of refractory disease, and after treatment with ruxolitinib. Laboratory testing was sent at each time point; X indicates

recurrent hemodynamic instability, and worsening liver and renal dysfunction. A bone marrow biopsy at that time demonstrated significant hemophagocytosis, which led to the diagnosis of refractory HLH.

Because alemtuzumab was not available for 72 hours and the patient continued to deteriorate, the decision was made to administer oral ruxolitinib in addition to dexamethasone. Ruxolitinib 2.5 mg twice per day was started based on dosing used for graft-versus-host disease treatment.^{6,7} Within 24 hours of starting ruxolitinib, our patient became afebrile, with rapid improvement in respiratory, liver, and hemodynamic function, improvement in inflammatory markers, and decrease in transfusion requirements (Figure 1). He no longer required inotropic support after 24 hours and was extubated within 3 days. Because he was refractory to etoposide, he did not receive any additional doses after the initiation of ruxolitinib. Genetic testing was performed and was negative for any known mutations in genes causing HLH (AP3B1, BLOC1S6, CD27, ITK, LYST, MAGT1, PRF1, RAB27A, SH2D1A, SLC7A7, STX11, STXBP2, UNC13D, and XIAP). Additionally, targeted exome sequencing was performed at our institution on a research protocol and was negative for any known mutations associated with immune deficiencies. The trigger for this patient's HLH remains unknown. The patient is currently well and successfully underwent treosulfan-based unrelated-donor bone marrow transplantation for treatment of his refractory HLH.

Results and discussion

There are few data surrounding salvage therapy for patients with refractory HLH. Patients for whom initial therapy fails have a poor prognosis, with a mortality rate of >50%.^{2,8} There are case reports and small case series of patients with refractory HLH treated with infliximab, anakinra, alemtuzumab, or daclizumab and a currently ongoing clinical trial using anti-IFN- γ .^{2,9-13} This is the first report of a patient with HLH who has been successfully treated with ruxolitinib.

Ruxolitinib inhibits activation of JAK1/2 and its downstream signaling pathways.¹⁴ The JAK1/2 pathway is activated by cytokines, specifically IFN- γ , IL-2, and IL-6, which are key contributors to inflammation in HLH.⁴ These cytokines bind to JAK receptors, leading to activation of the STAT family of transcription factors and regulation of downstream target genes.¹⁴ Blockade of this pathway decreases cytokine signaling and inflammation. JAK1/2 inhibitors, such as ruxolitinib,

Figure 1. (continued) that a criterion was met. (B) Temperature curve ($^{\circ}$ C). Patient remained febrile after etoposide and dexamethasone treatment and after anakinra treatment. Patient became afebrile and has remained afebrile after ruxolitinib was administered. (C) Ferritin and C-reactive protein (CRP). Ferritin remained elevated after etoposide and dexamethasone were started and, although eventually beginning to fall, rebounded at time of diagnosis of refractory HLH. Ferritin continued to decline to the normal range after the patient received ruxolitinib. Similarly, CRP, a nonspecific marker of inflammation, was elevated at the start of treatment and began to decline after etoposide and dexamethasone were started. CRP began to rise as the patient became refractory to treatment and then declined to normal range after ruxolitinib administration. (D) Soluble IL-2 receptor. Although not elevated at initial diagnosis, soluble IL-2 receptor increased with persistent fevers and inflammation and reached a maximum level just before start of ruxolitinib. After ruxolitinib initiation, soluble IL-2 receptor levels returned to normal.

Table 1. Patient's laboratory evaluation for etiology of secondary HLH

Laboratory results
Infectious
Blood and urine cultures: negative
Nasopharyngeal viral swabs: positive for enterovirus but repeat negative
Enterovirus blood PCR: negative
EBV PCR: negative
EBV IgG: positive; IgM: negative
CMV IgG: positive; IgM: negative
HIV antibody: negative
HIV RNA PCR: negative
Leishmaniasis antibody: negative
Endotracheal tube culture: normal flora
Bronchoalveolar lavage: negative
CSF encephalitis panel*: negative
Fungitel: negative
Galactomannan: negative
Histoplasmosis antibody: negative
Histoplasmosis antigen: negative
<i>Blastomyces</i> antibody: negative
<i>Blastomyces</i> antigen: negative
Hepatitis A IgG: positive; IgM: negative
Hepatitis B surface IgG: positive
Hepatitis B core IgG: negative
Hepatitis C IgG: negative
Malaria prep: negative
<i>Strongyloides</i> antibody: negative
<i>Brucella</i> IgG: negative; IgM: negative
Malaria prep: negative
Parvovirus: negative
Quantiferon gold: indeterminate
PPD: negative
Immunologic
IgG: 1890, IgA:400, IgE: 1124, IgM: 97 (mg/dL)
Normal vaccine response to tetanus and diphtheria, present but low response to <i>Haemophilus influenzae</i> type b
CD3 ⁺ : 310/mm ³ (CD4 <200/mm ³)
CD56: 0/mm ³
CD19: 212/mm ³
Rheumatologic
ACE: 40 U/L (normal range, 13-100 U/L)
C3: 173 mg/dL (normal, 80-156 mg/dL)
C4: 30.5 mg/dL (normal, 12-43 mg/dL)
Anti-RNP: 110 AU/mL (normal < 100 AU/mL)
Anti-SSA/SSB: <100 AU/mL (normal <100 AU/mL)
ANA titer: 80, nucleolar (normal <40)
Anti-dsDNA: 2 iU/mL (normal ≤4 iU/mL)
Anticardiolipin IgG and IgM: negative
Lupus anticoagulant: negative

Table 1. (continued)

Laboratory results
Antiproteinase 3 antibody: <1.0 AI (normal <1.0 AI)
Antimyeloperoxidase antibody: <1.0 AI (normal <1.0 AI)
Periodic fever syndrome panel†: negative
ADAMTS13 activity: 55% (assay can be inhibited by hyperbilirubinemia, normal >67%)
Creatine kinase: 49 iU/L (normal, 30-150 iU/L)
Cryoglobulins: positive
Haptoglobin: 151 mg/dL (normal, 43-212 mg/dL)
Oncologic
CT head, chest, abdomen negative for malignancy
Bone marrow flow cytometry negative for leukemia; cytogenetics normal

ACE, angiotensin converting enzyme; AI, antibody index; ANA, antinuclear antibodies; CMV, cytomegalovirus; CSF, cerebrospinal fluid; CT, computed tomography; EBV, Epstein-Barr virus; Ig, immunoglobulin; PCR, polymerase chain reaction; PPD, tuberculosis skin test.

*Encephalitis panel tested: NMDA receptor antibody, VGKC-complex antibody, CAD65 antibody, GABA-B receptor antibody, AMPA receptor antibody, ANNA-1, ANNA-2, ANNA-3, AGNA-1, PCA-1, PCA-2, PCA-Tr, amphiphysin antibody, CRMP-5-IgG.

†Periodic fever panel genes tested: ELA2, LPIN2, MEFV, MVK, NLRP3, PSTP1P1, TNFRSF1A.

are approved by the US Food and Drug Administration for the treatment of polycythemia vera and myelofibrosis in adults. Recent data support the efficacy of ruxolitinib in reducing the symptoms of proinflammatory diseases including rheumatoid arthritis, ulcerative colitis, myeloproliferative disorders, psoriasis, and graft-versus-host disease.^{6,7,15-22} In murine models, ruxolitinib has been shown to both prevent and treat HLH by decreasing cytokine production and inflammation via inhibition of STAT1 signaling.^{4,5} There is an active trial using ruxolitinib in adults with secondary HLH, but there have been no reports of pediatric patients who have received ruxolitinib for the treatment of HLH.

Our patient had a rapid clinical decline while receiving first-line therapy with etoposide and dexamethasone, necessitating urgent escalation in HLH treatment. Alemtuzumab was unavailable, and anakinra was ineffective, prompting further escalation to ruxolitinib. Within 24 hours of the first dose of ruxolitinib, the patient became afebrile, with dramatic improvement in inflammatory markers and organ function.

Whether our patient's improvement was due to ruxolitinib alone or in combination with anakinra is uncertain. However, the patient did not show clinical improvement until after the addition of ruxolitinib. We hypothesize that the cytokine blockade from ruxolitinib either alone or in combination with anakinra effectively halted the ongoing inflammatory dysregulation from HLH. Our patient tolerated ruxolitinib with only mild nausea that was well controlled with antiemetics. This symptom has subsequently resolved.

Our patient continued to receive ruxolitinib with weaning doses of dexamethasone biweekly as therapy for refractory HLH with normalization of HLH markers. He then underwent successful treosulfan-based unrelated-donor transplantation and was recently discharged from the hospital. Given this dramatic response, ruxolitinib should be evaluated further in pediatric clinical trials as targeted treatment for HLH.

Acknowledgments

This work was supported by the National Institutes of Health, National Center for Advancing Translational Sciences through grants UL1TR001436 and 1TL1TR001437.

The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health.

Authorship

Contribution: L.B. and L.P. drafted the initial manuscript; M.T., D.M., R.P., S.R., and J.T. revised the manuscript; and all authors approved the final manuscript.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

ORCID profiles: L.B., 0000-0002-1674-048X.

Correspondence: Julie Talano, Department of Pediatrics, Division of Hematology, Oncology, Blood and Marrow Transplant, Medical College of Wisconsin, 8701 Watertown Plank Rd, MFRC 3018, Milwaukee, WI 53226; e-mail: jtalano@mcw.edu.

References

1. Henter JI, Horne A, Aricó M, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. *Pediatr Blood Cancer*. 2007;48(2):124-131.
2. Marsh RA, Allen CE, McClain KL, et al. Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab. *Pediatr Blood Cancer*. 2013;60(1):101-109.
3. Marsh RA, Jordan MB, Talano JA, et al; Histiocyte Society Salvage Therapy Working Group. Salvage therapy for refractory hemophagocytic lymphohistiocytosis: a review of the published experience. *Pediatr Blood Cancer*. 2017;64(4).
4. Das R, Guan P, Sprague L, et al. Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis. *Blood*. 2016;127(13):1666-1675.
5. Maschalidi S, Sepulveda FE, Garrigue A, Fischer A, de Saint Basile G. Therapeutic effect of JAK1/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice. *Blood*. 2016;128(1):60-71.
6. Zeiser R, Burchert A, Lengerke C, et al. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. *Leukemia*. 2015;29(10):2062-2068.
7. Karras N, Jung J, Cotliar J. Ruxolitinib in a pediatric patient with chronic gvhd. *Biol Blood Marrow Transplant*. 2017;23(3):S236.
8. Trottestam H, Horne A, Aricó M, et al; Histiocyte Society. Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol. *Blood*. 2011;118(17):4577-4584.
9. Bruck N, Suttorp M, Kabus M, Heubner G, Gahr M, Pessler F. Rapid and sustained remission of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome through treatment with anakinra and corticosteroids. *J Clin Rheumatol*. 2011;17(1):23-27.
10. Henzan T, Nagafuji K, Tsukamoto H, et al. Success with infliximab in treating refractory hemophagocytic lymphohistiocytosis. *Am J Hematol*. 2006;81(1):59-61.
11. Strout MP, Seropian S, Berliner N. Alemtuzumab as a bridge to allogeneic SCT in atypical hemophagocytic lymphohistiocytosis. *Nat Rev Clin Oncol*. 2010;7(7):415-420.
12. Tomaske M, Amon O, Bosk A, Handgretinger R, Schneider EM, Niethammer D. Alpha-CD25 antibody treatment in a child with hemophagocytic lymphohistiocytosis. *Med Pediatr Oncol*. 2002;38(2):141-142.
13. Olin RL, Nichols KE, Naghashpour M, et al. Successful use of the anti-CD25 antibody daclizumab in an adult patient with hemophagocytic lymphohistiocytosis. *Am J Hematol*. 2008;83(9):747-749.
14. Kiu H, Nicholson SE. Biology and significance of the JAK/STAT signalling pathways. *Growth Factors*. 2012;30(2):88-106.
15. Fleischmann R, Kremer J, Cush J, et al; ORAL Solo Investigators. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. *N Engl J Med*. 2012;367(6):495-507.
16. Sandborn WJ, Ghosh S, Panes J, et al; Study A3921063 Investigators. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. *N Engl J Med*. 2012;367(7):616-624.
17. Mascarenhas J, Mughal TI, Verstovsek S. Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinib. *Curr Med Chem*. 2012;19(26):4399-4413.
18. Verstovsek S, Kantarjian HM, Estrov Z, et al. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. *Blood*. 2012;120(6):1202-1209.
19. Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. *N Engl J Med*. 2012;366(9):787-798.
20. Punwani N, Scherle P, Flores R, et al. Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis. *J Am Acad Dermatol*. 2012;67(4):658-664.
21. Xing L, Dai Z, Jabbari A, et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. *Nat Med*. 2014;20(9):1043-1049.
22. Spoerl S, Mathew NR, Bscheider M, et al. Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease. *Blood*. 2014;123(24):3832-3842.